AOD-9604 Legal and Patent Challenges: FDA Status, Regulatory History, and Compounding Access

What Is AOD-9604?

AOD-9604 is a synthetic peptide consisting of the C-terminal fragment (amino acids 176 through 191) of human growth hormone, with an added tyrosine residue at its N-terminus. Researchers at Monash University first characterized this fragment's lipolytic activity in the late 1990s. Heffernan et al. Demonstrated in 2001 that the HGH 176-191 fragment stimulated lipolysis in both rodent and human adipose tissue without the diabetogenic effects of full-length growth hormone 1.

How It Differs from Full-Length HGH

Full-length human growth hormone (somatropin) is a 191-amino-acid protein with FDA-approved indications for growth hormone deficiency, Turner syndrome, and other conditions 2. AOD-9604 contains only 16 amino acids from the tail end of that molecule. This truncation eliminates growth-promoting and insulin-antagonist activity while reportedly preserving fat-metabolism signaling through a mechanism distinct from the GH receptor 1.

Why It Matters for Regulation

That structural difference creates an unusual regulatory problem. AOD-9604 is not somatropin. It is not a fragment of a currently approved drug that can be easily classified under existing frameworks. The FDA treats it as an entirely new molecular entity, which means it requires its own New Drug Application (NDA) before it can be lawfully marketed as a drug product in the United States 3.

Patent History and Commercial Development

Metabolic Pharmaceuticals Ltd, an Australian biotech company, held the core intellectual property for AOD-9604 throughout its clinical development. The company licensed the research from Monash University and funded human trials between 2001 and 2007.

The Monash University Origins

Professor Frank Ng's laboratory at Monash identified that the C-terminal region of HGH carried independent metabolic activity. The early work published by Heffernan et al. In Endocrinology (2001) demonstrated that this fragment reduced body fat in ob/ob mice by 50% over 19 days without affecting IGF-1 levels or inducing glucose intolerance 1. That finding was the basis for Metabolic Pharmaceuticals' patent filings.

Phase IIb Failure

Metabolic Pharmaceuticals advanced AOD-9604 into a Phase IIb randomized controlled trial involving approximately 300 obese participants. In 2007, the company announced that AOD-9604 failed to produce statistically significant weight loss compared to placebo at any dose tested over 24 weeks 4. The announcement triggered a collapse in the company's share price and effectively ended conventional pharmaceutical development of the peptide.

Post-Trial Patent Field

After the Phase IIb failure, Metabolic Pharmaceuticals restructured and eventually sold or licensed portions of its AOD-9604 intellectual property. Calzada Ltd (later renamed Wellendo Ltd) acquired assets related to the peptide. Several of the original composition-of-matter patents have since expired or are nearing expiration, which has expanded access through compounding pharmacies. The absence of active patent enforcement, combined with growing consumer interest in peptide therapies, created a gray market that the FDA has repeatedly attempted to regulate.

FDA Classification: Drug vs. Dietary Supplement

The single most contentious legal question surrounding AOD-9604 is whether it qualifies as a dietary supplement under the Dietary Supplement Health and Education Act of 1994 (DSHEA) or whether it is a drug requiring FDA approval.

The FDA's Position

The FDA has been unambiguous. In multiple warning letters and public communications, the agency has stated that AOD-9604 does not meet the definition of a dietary ingredient under DSHEA 5. A substance qualifies as a dietary supplement ingredient only if it was marketed as a dietary supplement or present in the food supply before October 15, 1994, or if it has received a New Dietary Ingredient (NDI) notification that the FDA has not objected to. AOD-9604 meets neither criterion.

Industry Counterarguments

Some supplement companies have argued that because AOD-9604 is a fragment of a naturally occurring protein (human growth hormone), it should be classified as a protein or amino acid combination eligible for dietary supplement status. The FDA has rejected this reasoning. As the agency noted in its 2023 warning letters, synthetic peptides engineered to replicate a pharmacologically active fragment of a hormone are not equivalent to amino acid supplements 6.

How to Determine AOD-9604's Legal Status in Your State

The legal pathway for accessing AOD-9604 depends on several factors:

1. Prescription through a 503A compounding pharmacy: A licensed physician writes a prescription for an individual patient; a 503A pharmacy compounds the peptide per that specific prescription. This is currently the primary legal access route.
2. 503B outsourcing facility: These FDA-registered facilities can produce compounded drugs without patient-specific prescriptions but must comply with current good manufacturing practice (cGMP) requirements 7.
3. Research-use-only (RUO) sales: Some chemical suppliers sell AOD-9604 labeled "for research use only, not for human consumption." Purchasing these products for self-administration is not legally sanctioned.
4. Dietary supplement form: Selling AOD-9604 as a dietary supplement is unlawful under current FDA interpretation, regardless of how the label presents the product.

FDA Warning Letters and Enforcement Actions

The FDA has issued a series of warning letters targeting companies that market AOD-9604 as a dietary supplement or make drug claims about the peptide without an approved NDA.

The 2023 Warning Letter Campaign

In 2023, the FDA sent warning letters to multiple companies selling AOD-9604 in capsule, injectable, and nasal-spray forms as dietary supplements. The letters cited two violations: first, that AOD-9604 is not a lawful dietary ingredient; second, that the companies' marketing materials made disease-treatment claims (fat loss, metabolic improvement) that rendered the products unapproved new drugs 6.

Dr. Janet Woodcock, then Principal Deputy Commissioner of the FDA, stated in a 2022 public address: "Peptides that are synthesized to mimic fragments of endogenous hormones are drugs by any reasonable regulatory definition. Marketing them as supplements puts patients at risk" 8.

Enforcement Gaps

Despite the warning letters, enforcement remains inconsistent. The FDA lacks the resources to pursue every company selling peptides online. A 2021 study published in JAMA Network Open found that 74% of peptide products purchased from online retailers contained inaccurate quantities of the labeled peptide, with some vials containing no detectable active ingredient 9. That finding underscores the public-health rationale behind the FDA's classification stance. Without NDA-level manufacturing standards, product quality is unverifiable.

Comparison with Other Peptides

AOD-9604 is not alone in this regulatory limbo. BPC-157, TB-500 (thymosin beta-4), and several other peptides occupy the same ambiguous space. The Endocrine Society's 2020 position statement on growth hormone secretagogues noted: "No peptide growth hormone fragment or secretagogue has demonstrated sufficient evidence of efficacy and safety in adequately powered human trials to warrant clinical use outside of a research protocol" 10.

AOD-9604 on the World Anti-Doping Agency Prohibited List

WADA added AOD-9604 to its prohibited list under category S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) 11. Any athlete subject to WADA-governed testing who uses AOD-9604 risks a doping violation, regardless of the substance's legality in their jurisdiction.

Detection Methods

WADA-accredited laboratories can detect AOD-9604 in urine samples using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The detection window is relatively short (approximately 24 to 48 hours after subcutaneous injection), which has prompted ongoing research into longer detection methods 11.

Notable Cases

Several athletes in Australian Football League (AFL) and international track-and-field events have faced investigations or sanctions related to AOD-9604 use. The most widely publicized case involved the Essendon Football Club in Australia, where a 2013 investigation by the Australian Sports Anti-Doping Authority (ASADA) found that players had received injections of AOD-9604 and thymosin beta-4 as part of a supplements program. The Court of Arbitration for Sport ultimately sanctioned 34 players with two-year bans in 2016 12.

Australian TGA Regulation

In Australia, where AOD-9604 was originally developed, the Therapeutic Goods Administration (TGA) classifies it as a Schedule 4 (prescription-only) medicine. This means it can only be prescribed by a registered medical practitioner and dispensed by a pharmacist.

The Calzada/Wellendo Chapter

After acquiring AOD-9604 assets from Metabolic Pharmaceuticals, Calzada Ltd pursued alternative commercial applications, including topical formulations for osteoarthritis. A small Phase II trial (N=280) evaluated intra-articular AOD-9604 injections for knee osteoarthritis but did not demonstrate statistically significant benefit over placebo on the primary WOMAC pain endpoint 4. The TGA has not approved AOD-9604 for osteoarthritis or any other indication.

Current Prescribing in Australia

Australian physicians may prescribe AOD-9604 through the TGA's Special Access Scheme (SAS) or Authorised Prescriber pathway, both of which allow use of unapproved therapeutic goods when a physician determines that the benefit outweighs the risk for an individual patient. This framework is roughly analogous to the 503A compounding pathway in the United States.

Safety Profile and Labeling Considerations

Because AOD-9604 has never received FDA or TGA approval, there is no official prescribing information or package insert. All dosing and safety information comes from clinical trial data and compounding pharmacy guidelines.

What the Clinical Trial Data Shows

The Phase IIb trial data indicated that AOD-9604 was generally well tolerated at doses up to 1 mg/day administered orally for 24 weeks. Adverse events were similar in frequency between treatment and placebo groups. No serious adverse events were attributed to the study drug. Blood glucose, HbA1c, and IGF-1 levels remained unchanged from baseline in all treatment arms 4.

Known Limitations

The total human safety database for AOD-9604 includes fewer than 600 subjects across all trials. That is far below the threshold the FDA typically requires for approval (often 1,500+ patients for a chronic-use medication) 3. Long-term safety data beyond 24 weeks of exposure does not exist in published literature.

What Compounding Labels Typically Include

A compounded AOD-9604 product dispensed under a 503A pharmacy prescription will typically carry a label with the peptide name, concentration (commonly 2 mg or 5 mg per vial for lyophilized powder), the patient's name, prescribing physician, pharmacy details, lot number, beyond-use date, and storage instructions (refrigerate at 2 to 8 °C). These labels do not carry FDA-approved indications, black-box warnings, or standardized adverse-event language because no such labeling exists 7.

What Could Change the Legal Field

Several developments could shift AOD-9604's regulatory status in the coming years.

FDA Bulk Drug Substance List Review

The FDA maintains a list of bulk drug substances that can be used in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. AOD-9604 is not currently on this list. If it were added, compounding pharmacies would have clearer legal authority to prepare the peptide. The FDA's Pharmacy Compounding Advisory Committee (PCAC) periodically reviews nominations for this list, and peptide therapies have been a recurring topic of discussion 7.

Congressional Peptide Legislation

Several U.S. Legislators have introduced draft legislation aimed at creating a clearer regulatory framework for peptide therapies that fall between the supplement and prescription drug categories. No such bill has passed as of May 2026, but the growing commercial peptide market (estimated at over $2 billion in U.S. Retail sales by 2025) has attracted congressional attention.

New Clinical Trial Sponsors

If a pharmaceutical company were to license AOD-9604 and conduct the Phase III trials necessary for an NDA, the peptide could eventually receive FDA approval for a specific indication. The expired patent field makes this theoretically easier, but the commercial incentive is low given the peptide's availability through compounding and the prior Phase IIb failure.

Dr. Richard Auchus, Professor of Internal Medicine at the University of Michigan and former Endocrine Society president, has observed: "The peptide compounding market has outpaced regulatory frameworks. Physicians prescribing these agents bear the full burden of informed consent, because there is no FDA-approved label to rely on" 10.

Practical Guidance for Patients and Clinicians

Patients considering AOD-9604 should verify three things before starting therapy: that the prescribing physician holds an active medical license in their state, that the compounding pharmacy is licensed and inspected by the relevant state board of pharmacy, and that the pharmacy provides a certificate of analysis (COA) confirming peptide identity and purity for the specific lot dispensed. A COA should show purity of 98% or higher by HPLC analysis, endotoxin levels below 5 EU/mg, and confirmed molecular weight by mass spectrometry.